ARRY Array BioPharma Inc.

8.81
+0  (6%)
Previous Close 8.35
Open 8.43
Price To book 27.11
Market Cap 1.49B
Shares 169,007,000
Volume 2,726,588
Short Ratio 4.49
Av. Daily Volume 3,935,880

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet its primary endpoint - August 2016
Selumetinib - SELECT-1
Differentiated thyroid cancer
Phase 3 data released September 26, 2016 met primary endpoint. NDA filing due June or July 2017.
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial to be initiated in summer 2017.
ARRY 797
LMNA A/C-related dilated cardiomyopathy (DCM)
Phase 2 interim data due 2016 but no plans to advance program
ARRY-520 (Filanesib)
Refractory Multiple Myeloma Cancer
Phase 3 trial discontinued April 2016
Binimetinib - MILO
Recurrent low-grade serous ovarian cancer (LGSOC)
PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Binimetinib (NEMO)
NRAS melanoma - cancer
Phase 3 initiated June 2016. SPA announced September 2016. Plans to initiate randomization of patients in April 2017.
Encorafenib and cetuximab - BEACON CRC
BRAF-Mutant Colorectal Cancer

Latest News

  1. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  2. Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen
  3. Do Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't?
  4. Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down
  5. Will Array Biopharma's Melanoma Drugs Keep the Stock Soaring?
  6. How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
  7. Array Biopharma Withdraws Cancer Drug Application
  8. Apple, Array Biopharma, Alaska Air, and More: Here’s Why These Five Stocks Are in the Spotlight
  9. Biotech Premarket Movers: CytomX, Aevi, Esperion
  10. Array BioPharma Provides NEMO Update
  11. Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics
  12. Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : March 16, 2017
  13. 3 Biotech Stock Rockets With More Fuel in the Tank
  14. Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Ocera Therapeutics and Array Biopharma
  15. 5 Stock Picks Under $15 to Buy in March
  16. Array BioPharma To Present At The Cowen And Company Annual Healthcare Conference
  17. Cramer's lightning round: The only Chinese stock I will recommend
  18. How High Can Array BioPharma Inc. Stock Go?
  19. Want to Get In on Biotech? Check Out These 3 Stocks
  20. ETFs with exposure to Array BioPharma, Inc. : February 14, 2017